Hyperbaric oxygen therapy as additional treatment in deep sternal wound infections : a single center's experience by Litwinowicz, Radosław et al.
Kardiochirurgia i Torakochirurgia Polska 2016; 13 (3)198
Abstract
Introduction: Deep sternal wound infection (DSWI) is one of 
the most serious complications after cardiac surgery proce-
dures, observed in 5% of patients. Current standard medical 
therapy for DSWI includes antibiotics, surgical debridement, 
resuturing or negative pressure wound therapy (NPWT). Un-
fortunately, in some cases these methods are insufficient, and 
additional therapeutic options are needed. 
Aim: To assess the effects and usefulness of additional hy-
perbaric oxygen therapy (HBO2) in patients with DSWI after 
cardiac surgery procedures.
Material and methods: A retrospective analysis of 10 patients 
after cardiac surgery who developed DSWI in the period 2010–
2012 was performed. After 3 months of ineffective conven-
tional therapy including targeted antibiotic, surgical sternal 
debridement and NPWT, patients were qualified for additional 
HBO2 therapy. A total of 20 sessions of HBO2 therapy were 
performed, each 92 minutes long. 
Results: After 4 weeks of HBO2 treatment, 7 patients present-
ed complete wound healing with fibrous scar formation. One 
patient was qualified for the another cycle of HBO2 therapy 
with 20 additional sessions, and complete wound healing was 
observed. In 2 cases, after 5 and 19 sessions, HBO2 was inter-
rupted because of improper qualifications. 
Conclusions: The HBO2 as an additional therapy in DSWI was 
successful in 80% of cases, and no complications were ob-
served. However, due to the small number of published stud-
ies with a small number of patients, randomized, clinical trials 
are needed to assess the clinical results of HBO2 in DSWI after 
cardiac surgery procedures.
Key words: hyperbaric oxygen therapy, deep sternal wound 
infection.
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Streszczenie
Wstęp: Pooperacyjne zapalenie śródpiersia (DSWI) będące naj-
częstszym powikłaniem kardiochirurgicznym występuje u ok. 
5% pacjentów. Obecnie standardowym leczeniem DSWI jest 
antybiotykoterapia celowana, chirurgiczne opracowanie rany, 
resutura mostka oraz terapia podciśnieniowa (NPWT). Nieste-
ty w niektórych przypadkach terapia ta jest niewystarczająca 
i wymaga uzupełnienia o inne metody.
Cel: Ocena zastosowania tlenoterapii hiperbarycznej (HBO2) 
w leczeniu DSWI u pacjentów po operacjach kardiochirurgicz-
nych.
Materiał i metody: Retrospektywna analiza została przepro-
wadzona u 10 pacjentów z rozpoznanym DSWI operowanych 
w latach 2010–2012. Po 3 miesiącach nieefektywnego leczenia 
DSWI z wykorzystaniem antybiotykoterapii celowanej, chirur-
gicznego opracowania rany oraz NPWT pacjentów zakwalifiko-
wano do leczenia HBO2 w modelu 20 sesji, każda po 92 minuty.
Wyniki: Po 4 tygodniach HBO2 u 7 pacjentów nastąpiło całko-
wite zagojenie rany mostka. Jeden pacjent został skierowany 
na kolejny cykl zabiegów i także u niego nastąpiło zagojenie 
się rany. U dwóch pacjentów, po 5 i 19 sesjach, HBO2 została 
przerwana z powodu złej kwalifikacji do procedury.
Wnioski: Tlenoterapia hiperbaryczna okazała się skuteczna 
u 80% pacjentów z rozpoznanym DSWI. Wydaje się skutecz-
ną, tanią oraz bezpieczną metodą wspomagającą w leczeniu 
szczególnie trudnych, głębokich infekcji ran mostka. Ze wzglę-
du na małą liczbę opisywanych przypadków otrzymane wyniki 
powinny stanowić wstęp do dalszych badań.
Słowa kluczowe: tlenoterapia hiperbaryczna, pooperacyjne 
zapalenia śródpiersia.
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Introduction
Deep sternal wound infection (DSWI) is one of the most 
serious complications after cardiac surgery procedures. Ac-
cording to the literature, frequency of DSWI after cardiac 
surgery is from 0.5% to 5.3% with the early in hospital mor-
tality range from 10% to 47% [1–4]. Deep sternal wound in-
fection also increases the length of hospital stay, short- and 
long-term morbidity and medical costs [1, 4–7].
It is suggested that major mechanisms of DSWI are 
ischemia, hypoxia and nosocomial infections [7, 8]. Cur-
rent standard medical therapy for DSWI includes antibiot-
ics, surgical debridement, resuturing or negative pressure 
wound therapy (NPWT). Unfortunately, in some cases, 
these methods are insufficient and additional therapeutic 
options are needed.
In recent years hyperbaric oxygen therapy (HBO2) has 
become an approved treatment of patients with chronic, 
non-healing or difficult wounds. During HBO2 a short term 
of high pressure oxygen and atmospheric air is used to 
achieve hyperoxygenation of tissue. The dosage limits are 
determined by the toxicity of the O2 to the brain cells. The 
number of therapeutic sessions depends on the patient’s 
clinical status and the type of treated disorder. 
Hyperbaric oxygen therapy has a few different mecha-
nisms improving wound healing, including anti-inflamma-
tory effects, down-regulation of the cell adhesion molecules 
and diminished influence of leukocytes on the endothelium. 
Additionally, leukocyte killing capacity is enhanced, anaero-
bic bacteria are unable to grow, and production of clostridial 
α toxin is stopped. Hyperbaric oxygen therapy improves 
angiogenesis and vasculogenesis, and causes vasoconstric-
tion and edema reduction. A wide range of growth factors 
and processes (e.g. cellular collagen synthesis) are stimu-
lated by the availability of O2 in the cell matrix [9].
Aim
There are only a few papers about HBO2 therapy in pa-
tients with DSWI after a cardiac surgery procedure. The aim 
of this study was to present the effects and usefulness of 
HBO2 therapy in patients with deep sternal wound infec-
tions after a cardiac surgery operation. 
Material and methods 
In the period 2010–2012, ten patients who developed 
DSWI after cardiac surgery procedures were enrolled in the 
study. All data were collected retrospectively. Patients’ char-
acteristic are summarized in Table I. 
Deep sternal wound infection was diagnosed according 
to the following criteria defined by the Centers for Disease 
Control and Prevention [10]: 1 – an organism isolated from 
culture of mediastinal tissue or fluid; 2 – evidence of me-
diastinitis seen during operation; or 3 – presence of chest 
pain, sternal instability, or fever (> 38°C), and either puru-
lent drainage from the mediastinum, isolation of an organ-
ism present in a blood culture, or culture of the mediastinal 
area.
All patients were readmitted to hospital due to sternal 
dehiscence. Wound swabs were collected and empiric an-
tibiotic therapy was indicated. In all cases culture reports 
and antibiotic susceptibility tests showed mixed multi-re-
sistant bacterial or bacterial-fungal flora contaminations. 
Targeted antibiotic therapy was performed. The bacteriol-
ogy data are presented in Table II.
Beside the targeted antibiotic, every patient underwent 
surgical sternal debridement and NPWT. The decision of ad-
ditional HBO2 therapy was made after 3 months of ineffec-
tive conventional therapy.
Hyperbaric oxygen therapy was performed in a multi-
place hyperbaric chamber at Lesser Poland Center of Hy-
perbaric Therapy, Rydygier Hospital in Cracow. Hyperbaric 
oxygen therapy sessions were performed daily from Mon-
day to Friday with a break of 2 days. A total of 20 sessions 
were performed, each 92 minutes long.
Results
After 20 sessions of HBO2 therapy (4 weeks of treat-
ment), 7 (70%) patients presented complete wound healing 
with fibrous scar formation. One patient was qualified for 
another cycle of HBO2 therapy with 20 additional sessions, 
and after that complete wound healing with fibrous scar 
formation was observed. 
In 2 cases, patients received 5 and 19 of 20 sessions; 
however, the HBO2 course was interrupted because of im-
proper qualifications for HBO2 therapy. In both patients 
the sternum was completely destroyed by osteitis and the 
patients were qualified for sternal reconstructions with 
a musculocutaneous flap surgery procedure.
Tab. I. Patients’ characteristics
Parameter Result
Gender 60% male : 40% female 
Age Mean: 63 (range: 53–78) 
BMI [kg/m2] 30.3 (range: 24.8–33.5)
Procedure 
Isolated CABG – 40%
CABG + AVR – 20%
CABG + MV repair – 20%
CABG + MVR – 10%
Debranching – 10%
Hypertension 80% 
Diabetes mellitus 50% 
Hyperlipidemia 50%
Atrial fibrillation 20%
Renal failure 10%
COPD 10%
Peripheral vessel disease 10%
Hepatitis C 10%
EuroSCORE II 5.86 (range: 2–15.8) 
STS SCORE 2.167% (range: 0.4–3.4) 
STS infection PREOPERATIVE risk score 7.6% (range: 1.9–11.4) 
STS infection COMBINED risk score 5.76% (range: 1.3–10.7) 
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During HBO2 therapy no complications were observed. 
Figures 1 and 2 present wounds before and after HBO2 
therapy. 
Discussion
The incidence of postoperative DSWJ after cardiac sur-
gery is rather low and ranges from 0.5% to 5.3% [1–4, 11, 
12]. However, DSWI is one of the most serious complica-
tions, significantly increasing postoperative mortality, mor-
bidity, time of hospitalization, hospital costs and need for 
surgical re-intervention [13]. According to the literature, 
many factors have been found as DSWI risk factors and 
only some of them are modifiable [14–16]. Moreover, nowa-
days cardiac surgery patients mostly have at least two risk 
Tab. II. Microorganisms isolated from the patients’ wound swabs
Pathogen Percent of infected 
patients
Staphylococcus epidermidis MRS 80
Klebsiella pneumoniae ESBL 20
Enterobacter cloacae ESBL 20
Staphylococcus aureus MSSA 20
Staphylococcus haemolyticus MRS 20
Staphylococcus hominis MRS 20
Streptococcus agalactiae 10
Klebsiella ornithinolytica ESBL 10
Serratia marcescens 10
Pseudomonas aeruginosa 10
Enterococcus faecium 10
Acinetobacter baumannii 10
Acinetobacter haemolyticus 10
Clostridium difficile 10
Corynebacterium jeikeium 10
Corynebacterium amycolatum 10
Pediococcus pentosaceus 10
Bacillus spp. 10
Candida albicans 10
Candida parapsilosis 10
Staphylococcus aureus MRS 10
Staphylococcus epidermidis MSS 10
Fig.  1. A – Male patient before HBO2 therapy, B – the same male 
patient after HBO2 therapy 
A
B
Fig. 2. A – Female patient before HBO2 therapy, B – the same female patient after HBO2 therapy
A B
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factors for postoperative DSWI because of their older age 
and comorbidities [17]. 
Currently, debridement, directed antibiotics and NPWT 
are standard treatments in DSWI. Importantly, additional 
therapy algorithms may vary among surgeons. Past treat-
ment options have included closed suction and continuous 
irrigation. Current paradigms in the management of ster-
nal wound infection include surgical debridement, vacuum-
assisted closure therapy, flap coverage, and sternal plating 
[18]. Unfortunately, in the available literature there is still 
insufficient information about hyperbaric oxygen therapy 
as an alternative treatment option in DSWI [1, 2].
Hyperbaric oxygen therapy is widely used in surgery, 
with benefits observed in wound healing and limb salvage 
such as traumatic brain injury, chronic wounds, diabetic 
wounds, arterial ulcers, stasis ulcers, limb amputations, 
calciphylaxis, intractable vasculitic ulcers and others [19]. 
Hyperbaric oxygen therapy is defined as compression of 
the whole body with at least 1.4 atmospheres absolute 
pressure of pure oxygen [20]. Oxygen pressure increases 
and promotes collagen matrix formation, angiogenesis, 
cytoprotection, osteoclast/osteoblast activity and bone 
union, improves the effect of neutrophil response and in-
creases the synergistic effect of antibiotics [21–24]. 
It has been shown that sternal ischemia and hypoxia 
may play a main role in indication of DSWI [2, 8, 9]. For 
that reason the mechanism of HBO2 therapy may bring 
potential healing benefits. In our study, HBO2 therapy as 
an additional treatment in DSWI was successful in 80% of 
cases. Two cases were unsuccessful (20%) because of the 
completely destroyed sternum and wrong qualification for 
HBO2 therapy. 
In our study, the decision of HBO2 therapy was based on 
the physician’s personal clinical decision after 3 months of 
ineffective treatment. The extended 3-month period in our 
department was due to the qualifying period of ineffective 
treatment that must elapse to receive reimbursement for 
HBO2 treatment. However, it should be emphasized that in 
the author’s opinion HBO2 therapy should be started when 
there is the first clinical evidence that standard methods of 
treatment in DSWI are insufficient.
In the literature, the timing of HBO2 therapy varied de-
pending on the performed study. Barili et al. started HBO2 
therapy after diagnosis of DSWI [25]; Yu et al. started HBO2 
2 weeks to months after DSWI diagnosis [2], Higuchi et al. 
reported the initiation of HBO2 therapy for patients with 
persistent osteomyelitis after standard treatment [26]. 
However, the timing of HBO2 therapy for DSWI has been 
discussed, and all performed studies, including our results, 
present very good clinical results.
It should be mentioned that in all patients the conven-
tional LIMA harvesting was done by opening the cadaver’s 
chest with a mid-sternotomy incision in the CABG proce-
dure. Studies and investigational experiments showed that 
the internal mammary artery (IMA) is one of the most im-
portant risk factors of DSWI because of the IMA’s role in 
the blood supply of the sternum [8].
Currently, there are no guidelines or official clinical indi-
cations of HBO2 therapy in DSWI. There are only a few cases 
reports [2, 25, 26] and no randomized controlled trials [1, 27, 
28] to support or reject the use of HBO2 in DSWI. Most of 
the published articles present level V evidence, which pro-
vides weak evidence to support the use of HBO2 in treat-
ment, although the obtained results are encouraging [7]. 
What is also important, one of the main limitations of HBO2 
therapy is the distance between hyperbaric units and the 
cardiac surgery center. In our center we started to perform 
HBO2 therapy as additional treatment in DSWI shortly after 
the hyperbaric units were established in our town.
In our opinion, the potential benefits of HBO2 therapy 
as an additional treatment in DSWI are that it is a non-
invasive, non-burdensome and safe procedure. However, 
to confirm or refute the benefits of HBO2 therapy further, 
a blinded randomized controlled trial on a large group of 
patients is needed. 
Our study had several limitations. First, the number of 
cases was small. Second, there was no control group. Third, 
we performed a retrospective study; therefore some data 
may be missing or poorly documented. Fourth, the authors 
focused only on the clinical outcomes of studied patients. 
Conclusions
In this retrospective study, performed on a small group 
of patients, HBO2 as an additional therapy in deep sternal 
wound infections was successful in 80% of cases. It im-
proves sternum stabilization, wound sterilization and final 
healing. No complications of HBO2 therapy were observed. 
HBO2 is an alternative way of treatment but definitely 
worth considering, especially in patients in whom standard 
pharmacotherapy and NPWT have failed. However, due to 
the small number of published studies on a very small num-
ber of patients, randomized, clinical trials are needed to 
assess the clinical results of HBO2 in DSWI after cardiac 
surgery procedures. 
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